AD-115A, AD-1151

Phase 1Small molecule

AAddpharma Inc.

AD-115A, AD-1151 is one of 21 small molecule programs targeting Single Dose. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Single DoseCompleted

Single DosePhase 1

Completed

Competition

Competitive Landscape

26 competitors in Single Dose

#DrugCompanyPhaseTrials

Namenda

AbbVie

Phase 2

2 2

Lioresal

Novartis

Phase 2

1 3

Daliresp

AstraZeneca

Phase 2

1 4

Cialis

Eli Lilly

Phase 1

3 5

Opdivo

Bristol-Myers Squibb

Phase 1

1 6

Acoziborole

DDrugs for Neglected Diseases

Phase 3

1 7

LP-003

LLongbio Pharma

Phase 2

1 8

Psilocybin

COMPASS Pathways

Phase 1

1 9

Kytril

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Avodart

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Dose2 trials

The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

Completed·AAddpharma Inc.·Phase 1·NCT06902818·46 enrolled

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

Recruiting·AAddpharma Inc.·Phase 1·NCT07385235·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AD-115A, AD-1151. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AD-115A, AD-1151 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AD-115A, AD-1151. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Addpharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAddpharma Inc.

AD-115A, AD-1151

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Dose2 trials

References

Drug Info

Quick Facts

Related News